O	0	7	Peptide	Peptide	NN	B-NP
O	7	8	-	-	HYPH	I-NP
O	8	11	BSA	BSA	NN	I-NP
O	12	22	conjugates	conjugate	NNS	I-NP
O	23	25	as	as	IN	B-PP
O	26	36	diagnostic	diagnostic	JJ	B-NP
O	37	45	antigens	antigen	NNS	I-NP

O	46	48	To	To	TO	B-VP
O	49	56	analyse	analyse	VB	I-VP
O	57	60	the	the	DT	B-NP
O	61	70	potential	potential	NN	I-NP
O	71	73	of	of	IN	B-PP
O	74	77	the	the	DT	B-NP
O	78	86	peptides	peptide	NNS	I-NP
O	87	89	to	to	TO	B-VP
O	90	96	behave	behave	VB	I-VP
O	97	99	as	as	IN	B-PP
O	100	107	antigen	antigen	NN	B-NP
O	108	114	mimics	mimic	NNS	I-NP
O	114	115	,	,	,	O
O	116	121	their	their	PRP$	B-NP
O	122	129	ability	ability	NN	I-NP
O	130	132	to	to	TO	B-VP
O	133	138	react	react	VB	I-VP
O	139	143	with	with	IN	B-PP
O	144	147	IgM	IgM	NN	B-NP
O	148	158	antibodies	antibody	NNS	I-NP
O	159	163	from	from	IN	B-PP
O	164	175	individuals	individual	NNS	B-NP
O	176	184	infected	infect	VBN	B-VP
O	185	189	with	with	IN	B-PP
O	190	193	EBV	EBV	NN	B-NP
O	194	197	was	be	VBD	B-VP
O	198	206	assessed	assess	VBN	I-VP
O	206	207	.	.	.	O

O	208	210	In	In	IN	B-PP
O	211	214	our	our	PRP$	B-NP
O	215	223	previous	previous	JJ	I-NP
O	224	229	study	study	NN	I-NP
O	229	230	,	,	,	O
O	231	233	we	we	PRP	B-NP
O	234	246	demonstrated	demonstrate	VBD	B-VP
O	247	251	that	that	IN	B-SBAR
O	252	255	the	the	DT	B-NP
O	256	267	sensitivity	sensitivity	NN	I-NP
O	268	270	of	of	IN	B-PP
O	271	280	detection	detection	NN	B-NP
O	281	284	was	be	VBD	B-VP
O	285	292	greatly	greatly	RB	I-VP
O	293	301	improved	improve	VBN	I-VP
O	302	306	when	when	WRB	B-ADVP
O	307	310	the	the	DT	B-NP
O	311	319	peptides	peptide	NNS	I-NP
O	320	324	were	be	VBD	B-VP
O	325	332	coupled	couple	VBN	I-VP
O	333	335	to	to	TO	B-PP
O	336	337	a	a	DT	B-NP
O	338	345	carrier	carrier	NN	I-NP
O	346	354	molecule	molecule	NN	I-NP
O	355	359	such	such	JJ	B-PP
O	360	362	as	as	IN	I-PP
O	363	366	BSA	BSA	NN	B-NP
O	367	372	prior	prior	JJ	B-ADJP
O	373	375	to	to	TO	B-PP
O	376	390	immobilisation	immobilisation	NN	B-NP
O	391	395	onto	onto	IN	B-PP
O	396	397	a	a	DT	B-NP
O	398	403	solid	solid	JJ	I-NP
O	404	411	surface	surface	NN	I-NP
O	412	413	(	(	(	O
O	413	418	Casey	Casey	NNP	B-NP
O	419	421	et	et	FW	I-NP
O	422	424	al	al	FW	I-NP
O	424	425	.	.	FW	I-NP
O	425	426	,	,	,	O
O	427	431	2006	2006	CD	B-NP
O	431	432	)	)	)	O
O	432	433	.	.	.	O

O	434	438	This	This	DT	B-NP
O	439	447	strategy	strategy	NN	I-NP
O	448	451	was	be	VBD	B-VP
O	452	459	adopted	adopt	VBN	I-VP
O	460	462	to	to	TO	B-PP
O	463	467	test	test	NN	B-NP
O	468	476	peptides	peptide	NNS	I-NP
O	477	480	Eb1	Eb1	NN	I-NP
O	480	481	-	-	HYPH	B-NP
O	481	482	4	4	CD	I-NP
O	483	486	and	and	CC	I-NP
O	487	489	H1	H1	NN	I-NP
O	489	490	.	.	.	O

O	491	492	A	A	DT	B-NP
O	493	496	set	set	NN	I-NP
O	497	499	of	of	IN	B-PP
O	500	502	40	40	CD	B-NP
O	503	511	clinical	clinical	JJ	I-NP
B-Organism_substance	512	519	samples	sample	NNS	I-NP
O	520	524	that	that	WDT	B-NP
O	525	529	were	be	VBD	B-VP
O	530	540	classified	classify	VBN	I-VP
O	541	543	as	as	IN	B-PP
O	544	547	EBV	EBV	NN	B-NP
O	548	560	seropositive	seropositive	JJ	B-ADJP
O	561	562	(	(	(	O
O	562	563	n	n	NN	B-NP
O	564	565	=	=	SYM	B-VP
O	566	568	16	16	CD	B-NP
O	568	569	)	)	)	O
O	569	570	,	,	,	O
O	571	583	seronegative	seronegative	JJ	B-ADJP
O	584	585	(	(	(	O
O	585	586	n	n	NN	B-NP
O	587	588	=	=	SYM	B-VP
O	589	591	16	16	CD	B-NP
O	591	592	)	)	)	O
O	593	595	or	or	CC	O
O	596	607	potentially	potentially	RB	B-ADVP
O	608	613	cross	cross	AFX	O
O	613	614	-	-	HYPH	B-NP
O	614	622	reactive	reactive	JJ	I-NP
B-Organism_substance	623	627	sera	serum	NNS	I-NP
O	628	629	(	(	(	O
O	629	630	n	n	NN	B-NP
O	631	632	=	=	SYM	B-VP
O	633	634	8	8	CD	B-NP
O	634	635	)	)	)	O
O	636	640	were	be	VBD	B-VP
O	641	649	assessed	assess	VBN	I-VP
O	650	653	for	for	IN	B-PP
O	654	664	reactivity	reactivity	NN	B-NP
O	665	669	with	with	IN	B-PP
O	670	673	Eb1	Eb1	NN	B-NP
O	673	674	-	-	HYPH	B-NP
O	674	675	4	4	CD	I-NP
O	676	679	and	and	CC	I-NP
O	680	682	H1	H1	NN	I-NP
O	683	691	peptides	peptide	NNS	I-NP
O	692	704	individually	individually	RB	B-ADVP
O	704	705	.	.	.	O

O	706	709	The	The	DT	B-NP
O	710	713	cut	cut	VB	I-NP
O	713	714	-	-	HYPH	B-VP
O	714	717	off	off	RP	B-PRT
O	718	723	level	level	NN	B-NP
O	724	727	was	be	VBD	B-VP
O	728	735	defined	define	VBN	I-VP
O	736	738	as	as	IN	B-PP
O	739	742	the	the	DT	B-NP
O	743	747	mean	mean	JJ	I-NP
O	748	755	optical	optical	JJ	I-NP
O	756	763	density	density	NN	I-NP
O	764	766	of	of	IN	B-PP
O	767	770	the	the	DT	B-NP
O	771	783	seronegative	seronegative	JJ	I-NP
B-Organism_substance	784	791	samples	sample	NNS	I-NP
O	792	796	plus	plus	CC	O
O	797	798	3	3	CD	B-NP
O	799	807	standard	standard	JJ	I-NP
O	808	818	deviations	deviation	NNS	I-NP
O	819	824	shown	show	VBN	B-VP
O	825	827	as	as	IN	B-PP
O	828	829	a	a	DT	B-NP
O	830	834	line	line	NN	I-NP
O	835	837	on	on	IN	B-PP
O	838	841	the	the	DT	B-NP
O	842	848	graphs	graph	NNS	I-NP
O	849	851	in	in	IN	B-PP
O	852	855	Fig	Fig	NNP	B-NP
O	855	856	.	.	.	O

O	857	858	5	5	LS	B-LST
O	858	859	.	.	.	O

O	860	868	Readings	Reading	NNS	B-NP
O	869	874	above	above	IN	B-PP
O	875	879	this	this	DT	B-NP
O	880	885	level	level	NN	I-NP
O	886	890	were	be	VBD	B-VP
O	891	898	defined	define	VBN	I-VP
O	899	901	as	as	IN	B-PP
O	902	910	positive	positive	JJ	B-ADJP
O	911	914	and	and	CC	O
O	915	920	below	below	IN	B-PP
O	921	925	this	this	DT	B-NP
O	926	931	level	level	NN	I-NP
O	932	940	negative	negative	JJ	B-ADJP
O	940	941	.	.	.	O

O	942	945	The	The	DT	B-NP
O	946	950	same	same	JJ	I-NP
O	951	954	set	set	NN	I-NP
O	955	957	of	of	IN	B-PP
B-Organism_substance	958	965	samples	sample	NNS	B-NP
O	966	970	were	be	VBD	B-VP
O	971	979	analysed	analyse	VBN	I-VP
O	980	982	on	on	IN	B-PP
O	983	986	BSA	BSA	NN	B-NP
O	987	992	alone	alone	RB	B-ADVP
O	993	996	and	and	CC	O
O	997	1002	these	these	DT	B-NP
O	1003	1009	values	value	NNS	I-NP
O	1010	1014	were	be	VBD	B-VP
O	1015	1025	subtracted	subtract	VBN	I-VP
O	1026	1030	from	from	IN	B-PP
O	1031	1034	the	the	DT	B-NP
O	1035	1042	peptide	peptide	NN	I-NP
O	1042	1043	-	-	:	O
O	1043	1046	BSA	BSA	NN	B-NP
O	1047	1056	conjugate	conjugate	NN	I-NP
O	1057	1065	readings	reading	NNS	I-NP
O	1066	1069	and	and	CC	O
O	1070	1073	the	the	DT	B-NP
O	1074	1083	corrected	correct	VBN	I-NP
O	1084	1094	absorbance	absorbance	NN	I-NP
O	1095	1103	readings	reading	NNS	I-NP
O	1104	1108	were	be	VBD	B-VP
O	1109	1116	plotted	plot	VBN	I-VP
O	1117	1129	individually	individually	RB	B-ADVP
O	1130	1133	for	for	IN	B-PP
O	1134	1137	our	our	PRP$	B-NP
O	1138	1141	new	new	JJ	I-NP
O	1142	1150	peptides	peptide	NNS	I-NP
O	1151	1154	Eb1	Eb1	NN	I-NP
O	1154	1155	-	-	HYPH	B-NP
O	1155	1156	4	4	CD	I-NP
O	1157	1160	and	and	CC	I-NP
O	1161	1163	H1	H1	NN	I-NP
O	1164	1166	in	in	IN	B-PP
O	1167	1170	Fig	Fig	NNP	B-NP
O	1170	1171	.	.	.	O

O	1172	1173	5	5	LS	B-LST
O	1173	1174	.	.	.	O

O	1175	1180	There	There	EX	B-NP
O	1181	1184	was	be	VBD	B-VP
O	1185	1186	a	a	DT	B-NP
O	1187	1192	clear	clear	JJ	I-NP
O	1193	1203	difference	difference	NN	I-NP
O	1204	1206	in	in	IN	B-PP
O	1207	1210	the	the	DT	B-NP
O	1211	1220	detection	detection	NN	I-NP
O	1221	1223	of	of	IN	B-PP
O	1224	1236	seropositive	seropositive	JJ	B-NP
O	1237	1247	antibodies	antibody	NNS	I-NP
O	1248	1250	by	by	IN	B-PP
O	1251	1254	all	all	PDT	B-NP
O	1255	1258	the	the	DT	I-NP
O	1259	1267	peptides	peptide	NNS	I-NP
O	1268	1269	(	(	(	O
O	1269	1272	Fig	Fig	NNP	B-NP
O	1272	1273	.	.	.	I-NP
O	1274	1276	5A	5A	NN	I-NP
O	1276	1277	-	-	HYPH	B-NP
O	1277	1278	E	E	NN	I-NP
O	1278	1279	)	)	)	O
O	1280	1288	compared	compare	VBN	B-PP
O	1289	1293	with	with	IN	B-PP
O	1294	1297	the	the	DT	B-NP
O	1298	1306	analysis	analysis	NN	I-NP
O	1307	1309	of	of	IN	B-PP
O	1310	1313	BSA	BSA	NN	B-NP
O	1314	1319	alone	alone	RB	B-ADVP
O	1320	1321	(	(	(	O
O	1321	1324	Fig	Fig	NNP	B-NP
O	1324	1325	.	.	.	I-NP
O	1326	1328	5F	5F	NN	I-NP
O	1328	1329	)	)	)	O
O	1329	1330	,	,	,	O
O	1331	1335	with	with	IN	B-PP
O	1336	1339	the	the	DT	B-NP
O	1340	1348	majority	majority	NN	I-NP
O	1349	1351	of	of	IN	B-PP
O	1352	1362	absorbance	absorbance	NN	B-NP
O	1363	1371	readings	reading	NNS	I-NP
O	1372	1377	above	above	IN	B-PP
O	1378	1381	the	the	DT	B-NP
O	1382	1385	cut	cut	VB	I-NP
O	1385	1386	-	-	HYPH	B-VP
O	1386	1389	off	off	RP	B-PRT
O	1390	1395	level	level	NN	B-NP
O	1395	1396	.	.	.	O

O	1397	1399	We	We	PRP	B-NP
O	1400	1408	compared	compare	VBD	B-VP
O	1409	1412	the	the	DT	B-NP
O	1413	1420	ability	ability	NN	I-NP
O	1421	1423	of	of	IN	B-PP
O	1424	1427	our	our	PRP$	B-NP
O	1428	1433	panel	panel	NN	I-NP
O	1434	1436	of	of	IN	B-PP
O	1437	1444	peptide	peptide	NN	B-NP
O	1445	1454	mimotopes	mimotope	NNS	I-NP
O	1455	1457	to	to	TO	B-VP
O	1458	1460	be	be	VB	I-VP
O	1461	1471	recognised	recognise	VBN	I-VP
O	1472	1474	by	by	IN	B-PP
O	1475	1485	antibodies	antibody	NNS	B-NP
O	1486	1488	in	in	IN	B-PP
O	1489	1492	the	the	DT	B-NP
O	1493	1497	same	same	JJ	I-NP
O	1498	1501	set	set	NN	I-NP
O	1502	1504	of	of	IN	B-PP
O	1505	1517	seropositive	seropositive	JJ	B-NP
B-Organism_substance	1518	1525	samples	sample	NNS	I-NP
O	1526	1528	in	in	IN	B-PP
O	1529	1532	Fig	Fig	NNP	B-NP
O	1532	1533	.	.	.	O

O	1534	1536	6A	6A	NN	B-NP
O	1537	1540	and	and	CC	O
O	1541	1544	the	the	DT	B-NP
O	1545	1556	sensitivity	sensitivity	NN	I-NP
O	1557	1559	of	of	IN	B-PP
O	1560	1569	detection	detection	NN	B-NP
O	1570	1572	is	be	VBZ	B-VP
O	1573	1578	shown	show	VBN	I-VP
O	1579	1581	in	in	IN	B-PP
O	1582	1585	Fig	Fig	NNP	B-NP
O	1585	1586	.	.	.	O

O	1587	1589	6B	6B	NN	B-NP
O	1589	1590	.	.	.	O

O	1591	1593	We	We	PRP	B-NP
O	1594	1598	also	also	RB	B-ADVP
O	1599	1607	included	include	VBD	B-VP
O	1608	1610	F1	F1	NN	B-NP
O	1611	1614	and	and	CC	I-NP
O	1615	1620	Gp125	Gp125	NN	I-NP
O	1621	1630	mimotopes	mimotope	NNS	I-NP
O	1631	1639	specific	specific	JJ	B-ADJP
O	1640	1643	for	for	IN	B-PP
O	1644	1647	two	two	CD	B-NP
O	1648	1652	mAbs	mAb	NNS	I-NP
O	1653	1655	in	in	IN	B-PP
O	1656	1659	our	our	PRP$	B-NP
O	1660	1668	previous	previous	JJ	I-NP
O	1669	1674	study	study	NN	I-NP
O	1675	1676	(	(	(	O
O	1676	1681	Casey	Casey	NNP	B-NP
O	1682	1684	et	et	FW	I-NP
O	1685	1687	al	al	FW	I-NP
O	1687	1688	.	.	FW	I-NP
O	1688	1689	,	,	,	O
O	1690	1694	2006	2006	CD	B-NP
O	1694	1695	)	)	)	O
O	1695	1696	.	.	.	O

O	1697	1699	Of	Of	IN	B-PP
O	1700	1703	the	the	DT	B-NP
O	1704	1712	peptides	peptide	NNS	I-NP
O	1713	1723	identified	identify	VBN	B-VP
O	1724	1728	from	from	IN	B-PP
O	1729	1739	polyclonal	polyclonal	JJ	B-NP
B-Organism_substance	1740	1744	sera	serum	NNS	I-NP
O	1745	1748	Eb1	Eb1	NN	I-NP
O	1748	1749	,	,	,	O
O	1750	1755	Gp125	Gp125	NN	B-NP
O	1756	1759	and	and	CC	I-NP
O	1760	1762	F1	F1	NN	I-NP
O	1763	1766	had	have	VBD	B-VP
O	1767	1770	the	the	DT	B-NP
O	1771	1778	highest	high	JJS	I-NP
O	1779	1790	sensitivity	sensitivity	NN	I-NP
O	1791	1792	(	(	(	O
O	1792	1794	94	94	CD	B-NP
O	1794	1795	%	%	NN	I-NP
O	1795	1796	)	)	)	O
O	1796	1797	.	.	.	O

O	1798	1806	Slightly	Slightly	RB	B-NP
O	1807	1812	lower	low	JJR	I-NP
O	1813	1824	sensitivity	sensitivity	NN	I-NP
O	1825	1828	was	be	VBD	B-VP
O	1829	1837	observed	observe	VBN	I-VP
O	1838	1841	for	for	IN	B-PP
O	1842	1845	Eb2	Eb2	NN	B-NP
O	1845	1846	,	,	,	O
O	1847	1848	3	3	CD	B-NP
O	1849	1852	and	and	CC	I-NP
O	1853	1854	4	4	CD	I-NP
O	1855	1856	(	(	(	O
O	1856	1858	88	88	CD	B-NP
O	1858	1859	%	%	NN	I-NP
O	1859	1860	)	)	)	O
O	1861	1864	and	and	CC	O
O	1865	1867	H1	H1	NN	B-NP
O	1868	1875	peptide	peptide	NN	I-NP
O	1876	1879	had	have	VBD	B-VP
O	1880	1883	the	the	DT	B-NP
O	1884	1890	lowest	low	JJS	I-NP
O	1891	1902	sensitivity	sensitivity	NN	I-NP
O	1903	1904	(	(	(	O
O	1904	1906	81	81	CD	B-NP
O	1906	1907	%	%	NN	I-NP
O	1907	1908	)	)	)	O
O	1909	1911	as	as	IN	B-SBAR
O	1912	1922	summarised	summarise	VBN	B-VP
O	1923	1925	in	in	IN	B-PP
O	1926	1929	Fig	Fig	NNP	B-NP
O	1929	1930	.	.	.	O

O	1931	1933	6B	6B	NN	B-NP
O	1933	1934	.	.	.	O

O	1935	1938	The	The	DT	B-NP
O	1939	1950	sensitivity	sensitivity	NN	I-NP
O	1951	1953	of	of	IN	B-PP
O	1954	1956	F1	F1	NN	B-NP
O	1957	1960	and	and	CC	I-NP
O	1961	1966	Gp125	Gp125	NN	I-NP
O	1967	1970	was	be	VBD	B-VP
O	1971	1978	similar	similar	JJ	B-ADJP
O	1979	1981	to	to	TO	B-PP
O	1982	1986	that	that	DT	B-NP
O	1987	1995	produced	produce	VBN	B-VP
O	1996	1998	by	by	IN	B-PP
O	1999	2002	the	the	DT	B-NP
O	2003	2012	mimotopes	mimotope	NNS	I-NP
O	2013	2021	selected	select	VBN	B-VP
O	2022	2024	in	in	IN	B-PP
O	2025	2028	our	our	PRP$	B-NP
O	2029	2037	previous	previous	JJ	I-NP
O	2038	2043	study	study	NN	I-NP
O	2043	2044	,	,	,	O
O	2045	2047	95	95	CD	B-NP
O	2047	2048	%	%	NN	I-NP
O	2049	2052	for	for	IN	B-PP
O	2053	2055	F1	F1	NN	B-NP
O	2056	2059	and	and	CC	O
O	2060	2062	92	92	CD	B-NP
O	2062	2063	%	%	NN	I-NP
O	2064	2067	for	for	IN	B-PP
O	2068	2073	Gp125	Gp125	NN	B-NP
O	2073	2074	.	.	.	O

O	2075	2078	Fig	Fig	NNP	B-NP
O	2078	2079	.	.	.	O

O	2080	2081	5	5	LS	B-LST

O	2082	2092	Evaluation	Evaluation	NN	B-NP
O	2093	2095	of	of	IN	B-PP
O	2096	2104	peptides	peptide	NNS	B-NP
O	2105	2108	Eb1	Eb1	NN	I-NP
O	2108	2109	-	-	HYPH	B-NP
O	2109	2110	4	4	CD	I-NP
O	2111	2114	and	and	CC	I-NP
O	2115	2117	H1	H1	NN	I-NP
O	2118	2125	coupled	couple	VBN	B-VP
O	2126	2128	to	to	TO	B-PP
O	2129	2132	BSA	BSA	NN	B-NP
O	2133	2135	as	as	IN	B-PP
O	2136	2139	EBV	EBV	NN	B-NP
O	2140	2150	diagnostic	diagnostic	JJ	I-NP
O	2151	2159	reagents	reagent	NNS	I-NP
O	2159	2160	.	.	.	O

O	2161	2166	Human	Human	JJ	B-NP
B-Organism_substance	2167	2172	serum	serum	NN	I-NP
O	2173	2174	(	(	(	O
O	2174	2175	n	n	NN	B-NP
O	2176	2177	=	=	SYM	B-VP
O	2178	2180	40	40	CD	B-NP
O	2180	2181	)	)	)	O
O	2182	2192	previously	previously	RB	B-VP
O	2193	2201	analysed	analyse	VBN	I-VP
O	2202	2207	using	use	VBG	B-VP
O	2208	2209	a	a	DT	B-NP
O	2210	2220	diagnostic	diagnostic	JJ	I-NP
O	2221	2225	test	test	NN	I-NP
O	2226	2229	for	for	IN	B-PP
O	2230	2233	VCA	VCA	NN	B-NP
O	2234	2237	IgM	IgM	NN	I-NP
O	2238	2241	was	be	VBD	B-VP
O	2242	2249	allowed	allow	VBN	I-VP
O	2250	2252	to	to	TO	I-VP
O	2253	2258	react	react	VB	I-VP
O	2259	2263	with	with	IN	B-PP
O	2264	2267	the	the	DT	B-NP
O	2268	2276	peptides	peptide	NNS	I-NP
O	2277	2280	and	and	CC	O
O	2281	2284	the	the	DT	B-NP
O	2285	2290	bound	bind	VBN	I-NP
O	2291	2294	IgM	IgM	NN	I-NP
O	2295	2305	antibodies	antibody	NNS	I-NP
O	2306	2310	were	be	VBD	B-VP
O	2311	2319	detected	detect	VBN	I-VP
O	2320	2325	using	use	VBG	B-VP
O	2326	2330	anti	anti	AFX	B-NP
O	2330	2331	-	-	HYPH	I-NP
O	2331	2336	human	human	JJ	I-NP
O	2337	2340	IgM	IgM	NN	I-NP
O	2341	2344	HRP	HRP	NN	I-NP
O	2344	2345	.	.	.	O

O	2346	2349	The	The	DT	B-NP
O	2350	2360	absorbance	absorbance	NN	I-NP
O	2361	2369	readings	reading	NNS	I-NP
O	2370	2373	for	for	IN	B-PP
O	2374	2375	1	1	CD	B-NP
O	2376	2377	(	(	(	O
O	2377	2385	positive	positive	JJ	B-ADJP
O	2385	2386	)	)	)	O
O	2386	2387	,	,	,	O
O	2388	2389	2	2	CD	B-NP
O	2390	2391	(	(	(	O
O	2391	2399	negative	negative	JJ	B-ADJP
O	2399	2400	)	)	)	O
O	2401	2404	and	and	CC	O
O	2405	2413	putative	putative	JJ	B-NP
O	2414	2419	cross	cross	AFX	I-NP
O	2419	2420	-	-	HYPH	I-NP
O	2420	2428	reactive	reactive	JJ	I-NP
B-Organism_substance	2429	2433	sera	serum	NNS	I-NP
O	2434	2437	for	for	IN	B-PP
O	2438	2439	3	3	CD	B-NP
O	2440	2441	(	(	(	O
O	2441	2446	Parvo	Parvo	NN	B-NP
O	2446	2447	)	)	)	O
O	2447	2448	,	,	,	O
O	2449	2450	4	4	CD	B-NP
O	2451	2452	(	(	(	O
O	2452	2455	HSV	HSV	NN	B-NP
O	2455	2456	)	)	)	O
O	2456	2457	,	,	,	O
O	2458	2459	5	5	CD	B-NP
O	2460	2461	(	(	(	O
O	2461	2464	CMV	CMV	NN	B-NP
O	2464	2465	)	)	)	O
O	2466	2469	and	and	CC	O
O	2470	2471	6	6	CD	B-NP
O	2472	2473	(	(	(	O
O	2473	2475	RF	RF	NN	B-NP
O	2475	2476	)	)	)	O
O	2477	2480	are	be	VBP	B-VP
O	2481	2488	plotted	plot	VBN	I-VP
O	2489	2492	for	for	IN	B-PP
O	2493	2494	(	(	(	O
O	2494	2495	A	A	NN	B-NP
O	2495	2496	)	)	)	O
O	2497	2500	Eb1	Eb1	NN	B-NP
O	2500	2501	,	,	,	O
O	2502	2503	(	(	(	O
O	2503	2504	B	B	NN	B-NP
O	2504	2505	)	)	)	O
O	2506	2509	Eb2	Eb2	NN	B-NP
O	2509	2510	,	,	,	O
O	2511	2512	(	(	(	O
O	2512	2513	C	C	NN	B-NP
O	2513	2514	)	)	)	O
O	2515	2518	Eb3	Eb3	NN	B-NP
O	2518	2519	,	,	,	O
O	2520	2521	(	(	(	O
O	2521	2522	D	D	NNP	O
O	2522	2523	)	)	)	O
O	2524	2527	Eb4	Eb4	NN	B-NP
O	2527	2528	,	,	,	O
O	2529	2530	(	(	(	O
O	2530	2531	E	E	NNP	O
O	2531	2532	)	)	)	O
O	2533	2535	H1	H1	NN	B-NP
O	2536	2539	and	and	CC	O
O	2540	2541	(	(	(	O
O	2541	2542	F	F	NN	B-NP
O	2542	2543	)	)	)	O
O	2544	2547	BSA	BSA	NN	B-NP
O	2547	2548	,	,	,	O
O	2549	2561	respectively	respectively	RB	B-ADVP
O	2561	2562	.	.	.	O

O	2563	2566	The	The	DT	B-NP
O	2567	2570	cut	cut	VB	I-NP
O	2570	2571	-	-	HYPH	B-VP
O	2571	2574	off	off	RP	B-PRT
O	2575	2580	value	value	NN	B-NP
O	2581	2583	is	be	VBZ	B-VP
O	2584	2591	defined	define	VBN	I-VP
O	2592	2594	as	as	IN	B-PP
O	2595	2598	the	the	DT	B-NP
O	2599	2603	mean	mean	NN	I-NP
O	2604	2606	of	of	IN	B-PP
O	2607	2610	the	the	DT	B-NP
O	2611	2619	negative	negative	JJ	I-NP
O	2620	2630	population	population	NN	I-NP
O	2631	2632	+	+	SYM	B-NP
O	2632	2635	3SD	3SD	NN	I-NP
O	2636	2645	indicated	indicate	VBN	B-VP
O	2646	2648	by	by	IN	B-PP
O	2649	2650	a	a	DT	B-NP
O	2651	2656	solid	solid	JJ	I-NP
O	2657	2667	horizontal	horizontal	JJ	I-NP
O	2668	2672	line	line	NN	I-NP
O	2672	2673	;	;	:	O
O	2674	2679	since	since	IN	B-SBAR
O	2680	2685	there	there	EX	B-NP
O	2686	2690	were	be	VBD	B-VP
O	2691	2693	no	no	DT	B-NP
O	2694	2699	false	false	JJ	I-NP
O	2700	2709	positives	positive	NNS	I-NP
O	2709	2710	,	,	,	O
O	2711	2714	the	the	DT	B-NP
O	2715	2726	specificity	specificity	NN	I-NP
O	2727	2730	for	for	IN	B-PP
O	2731	2735	each	each	DT	B-NP
O	2736	2744	mimotope	mimotope	NN	I-NP
O	2745	2748	was	be	VBD	B-VP
O	2749	2752	100	100	CD	B-NP
O	2752	2753	%	%	NN	I-NP
O	2753	2754	.	.	.	O

O	2755	2758	Fig	Fig	NNP	B-NP
O	2758	2759	.	.	.	O

O	2760	2761	6	6	CD	B-NP

O	2762	2772	Comparison	Comparison	NN	B-NP
O	2773	2775	of	of	IN	B-PP
O	2776	2779	the	the	DT	B-NP
O	2780	2792	reactivities	reactivity	NNS	I-NP
O	2793	2795	of	of	IN	B-PP
O	2796	2799	our	our	PRP$	B-NP
O	2800	2805	panel	panel	NN	I-NP
O	2806	2808	of	of	IN	B-PP
O	2809	2818	mimotopes	mimotope	NNS	B-NP
O	2819	2822	Eb1	Eb1	NN	I-NP
O	2822	2823	-	-	HYPH	B-NP
O	2823	2824	4	4	CD	I-NP
O	2824	2825	,	,	,	I-NP
O	2826	2828	H1	H1	NN	I-NP
O	2828	2829	,	,	,	I-NP
O	2830	2832	F1	F1	NN	I-NP
O	2833	2836	and	and	CC	I-NP
O	2837	2842	Gp125	Gp125	NN	I-NP
O	2843	2853	conjugated	conjugate	VBN	B-VP
O	2854	2856	to	to	TO	B-PP
O	2857	2860	BSA	BSA	NN	B-NP
O	2861	2865	with	with	IN	B-PP
O	2866	2869	EBV	EBV	NN	B-NP
O	2870	2873	IgM	IgM	NN	I-NP
O	2873	2874	-	-	HYPH	B-NP
O	2874	2882	positive	positive	JJ	I-NP
B-Organism_substance	2883	2887	sera	serum	NNS	I-NP
O	2888	2889	(	(	(	O
O	2889	2890	n	n	NN	B-NP
O	2891	2892	=	=	SYM	B-VP
O	2893	2895	16	16	CD	B-NP
O	2895	2896	)	)	)	O
O	2897	2907	absorbance	absorbance	NN	B-NP
O	2908	2914	values	value	NNS	I-NP
O	2915	2918	are	be	VBP	B-VP
O	2919	2926	plotted	plot	VBN	I-VP
O	2927	2930	and	and	CC	O
O	2931	2934	the	the	DT	B-NP
O	2935	2938	cut	cut	VB	I-NP
O	2938	2939	-	-	HYPH	B-ADJP
O	2939	2942	off	off	RP	B-PRT
O	2943	2949	levels	level	NNS	B-NP
O	2950	2953	are	be	VBP	B-VP
O	2954	2962	depicted	depict	VBN	I-VP
O	2963	2965	by	by	IN	B-PP
O	2966	2967	a	a	DT	B-NP
O	2968	2978	horizontal	horizontal	JJ	I-NP
O	2979	2983	line	line	NN	I-NP
O	2984	2986	in	in	IN	B-PP
O	2987	2988	(	(	(	O
O	2988	2989	A	A	NN	B-NP
O	2989	2990	)	)	)	O
O	2990	2991	.	.	.	O

O	2992	2993	(	(	(	O
O	2993	2994	B	B	NN	B-NP
O	2994	2995	)	)	)	O
O	2996	3003	Summary	Summary	NNP	B-NP
O	3004	3006	of	of	IN	B-PP
O	3007	3010	the	the	DT	B-NP
O	3011	3016	false	false	JJ	I-NP
O	3016	3017	-	-	HYPH	I-NP
O	3017	3025	negative	negative	JJ	I-NP
O	3026	3033	results	result	NNS	I-NP
O	3034	3038	from	from	IN	B-PP
O	3039	3042	the	the	DT	B-NP
O	3043	3044	5	5	CD	I-NP
O	3044	3045	/	/	SYM	I-NP
O	3045	3047	16	16	CD	I-NP
B-Organism_substance	3048	3053	serum	serum	NN	I-NP
I-Organism_substance	3054	3061	samples	sample	NNS	I-NP
O	3062	3074	seropositive	seropositive	JJ	B-ADJP
O	3075	3078	for	for	IN	B-PP
O	3079	3082	IgM	IgM	NN	B-NP
O	3083	3086	EBV	EBV	NN	I-NP
O	3087	3090	and	and	CC	O
O	3091	3094	the	the	DT	B-NP
O	3095	3102	overall	overall	JJ	I-NP
O	3103	3114	sensitivity	sensitivity	NN	I-NP
O	3115	3118	for	for	IN	B-PP
O	3119	3123	each	each	DT	B-NP
O	3124	3132	mimotope	mimotope	NN	I-NP
O	3133	3136	for	for	IN	B-PP
O	3137	3146	diagnosis	diagnosis	NN	B-NP
O	3147	3149	of	of	IN	B-PP
O	3150	3153	EBV	EBV	NN	B-NP
O	3154	3157	IgM	IgM	NN	I-NP
O	3158	3168	antibodies	antibody	NNS	I-NP
O	3168	3169	.	.	.	O

O	3170	3172	We	We	PRP	B-NP
O	3173	3177	also	also	RB	B-ADVP
O	3178	3188	considered	consider	VBD	B-VP
O	3189	3194	which	which	WDT	B-NP
O	3195	3207	seropositive	seropositive	JJ	B-NP
O	3208	3211	EBV	EBV	NN	I-NP
B-Organism_substance	3212	3219	samples	sample	NNS	I-NP
O	3220	3229	contained	contain	VBD	B-VP
O	3230	3240	antibodies	antibody	NNS	B-NP
O	3241	3245	that	that	WDT	B-NP
O	3246	3249	did	do	VBD	B-VP
O	3250	3253	not	not	RB	I-VP
O	3254	3263	recognise	recognise	VB	I-VP
O	3264	3267	the	the	DT	B-NP
O	3268	3273	panel	panel	NN	I-NP
O	3274	3276	of	of	IN	B-PP
O	3277	3285	peptides	peptide	NNS	B-NP
O	3285	3286	,	,	,	O
O	3287	3288	i	i	NN	B-NP
O	3288	3289	.	.	.	O
O	3289	3290	e	e	NN	B-NP
O	3290	3291	.	.	.	O
O	3292	3297	false	false	JJ	B-NP
O	3297	3298	-	-	HYPH	I-NP
O	3298	3306	negative	negative	JJ	I-NP
O	3307	3315	readings	reading	NNS	I-NP
O	3315	3316	,	,	,	O
O	3317	3323	listed	list	VBN	B-VP
O	3324	3326	in	in	IN	B-PP
O	3327	3330	Fig	Fig	NNP	B-NP
O	3330	3331	.	.	.	O

O	3332	3334	6B	6B	NN	B-NP
O	3334	3335	.	.	.	O

O	3336	3339	The	The	DT	B-NP
O	3340	3350	antibodies	antibody	NNS	I-NP
O	3351	3353	in	in	IN	B-PP
B-Organism_substance	3354	3359	serum	serum	NN	B-NP
O	3360	3361	1	1	CD	I-NP
O	3362	3363	(	(	(	O
O	3363	3365	s1	s1	NN	B-NP
O	3365	3366	)	)	)	O
O	3367	3371	were	be	VBD	B-VP
O	3372	3382	unreactive	unreactive	JJ	B-ADJP
O	3383	3387	with	with	IN	B-PP
O	3388	3391	all	all	DT	B-NP
O	3392	3394	of	of	IN	B-PP
O	3395	3398	the	the	DT	B-NP
O	3399	3407	peptides	peptide	NNS	I-NP
O	3408	3418	identified	identify	VBN	B-VP
O	3419	3421	in	in	IN	B-PP
O	3422	3426	this	this	DT	B-NP
O	3427	3432	study	study	NN	I-NP
O	3432	3433	,	,	,	O
O	3434	3436	s2	s2	NN	B-NP
O	3437	3440	was	be	VBD	B-VP
O	3441	3444	not	not	RB	O
O	3445	3453	reactive	reactive	JJ	B-ADJP
O	3454	3458	with	with	IN	B-PP
O	3459	3462	Eb3	Eb3	NN	B-NP
O	3462	3463	,	,	,	I-NP
O	3464	3467	Eb4	Eb4	NN	I-NP
O	3468	3471	and	and	CC	I-NP
O	3472	3474	H1	H1	NN	I-NP
O	3475	3478	and	and	CC	I-NP
O	3479	3481	s3	s3	NN	I-NP
O	3482	3485	was	be	VBD	B-VP
O	3486	3496	unreactive	unreactive	JJ	B-ADJP
O	3497	3501	with	with	IN	B-PP
O	3502	3504	H1	H1	NN	B-NP
O	3504	3505	.	.	.	O

O	3506	3511	Gp125	Gp125	NN	B-NP
O	3512	3515	and	and	CC	I-NP
O	3516	3518	F1	F1	NN	I-NP
O	3519	3523	that	that	WDT	B-NP
O	3524	3528	were	be	VBD	B-VP
O	3529	3537	selected	select	VBN	I-VP
O	3538	3540	in	in	IN	B-PP
O	3541	3544	our	our	PRP$	B-NP
O	3545	3553	previous	previous	JJ	I-NP
O	3554	3559	study	study	NN	I-NP
O	3560	3564	were	be	VBD	B-VP
O	3565	3575	recognised	recognise	VBN	I-VP
O	3576	3578	by	by	IN	B-PP
O	3579	3581	s1	s1	NN	B-NP
O	3581	3582	,	,	,	O
O	3583	3584	2	2	CD	B-NP
O	3585	3588	and	and	CC	I-NP
O	3589	3590	3	3	CD	I-NP
O	3590	3591	;	;	:	O
O	3592	3599	however	however	RB	B-ADVP
O	3599	3600	,	,	,	O
O	3601	3604	two	two	CD	B-NP
O	3605	3614	different	different	JJ	I-NP
B-Organism_substance	3615	3620	serum	serum	NN	I-NP
I-Organism_substance	3621	3628	samples	sample	NNS	I-NP
O	3629	3630	(	(	(	O
O	3630	3632	s4	s4	NN	B-NP
O	3633	3636	and	and	CC	O
O	3637	3638	5	5	CD	B-NP
O	3638	3639	)	)	)	O
O	3640	3643	did	do	VBD	B-VP
O	3644	3647	not	not	RB	I-VP
O	3648	3657	recognise	recognise	VB	I-VP
O	3658	3660	F1	F1	NN	B-NP
O	3661	3663	or	or	CC	I-NP
O	3664	3669	Gp125	Gp125	NN	I-NP
O	3669	3670	,	,	,	O
O	3671	3683	respectively	respectively	RB	B-ADVP
O	3683	3684	.	.	.	O

O	3685	3689	This	This	DT	B-NP
O	3690	3702	demonstrates	demonstrate	VBZ	B-VP
O	3703	3707	that	that	IN	B-SBAR
O	3708	3718	individual	individual	JJ	B-NP
O	3719	3727	peptides	peptide	NNS	I-NP
O	3728	3731	are	be	VBP	B-VP
O	3732	3735	not	not	RB	I-VP
O	3736	3746	recognised	recognise	VBN	I-VP
O	3747	3749	by	by	IN	B-PP
O	3750	3753	all	all	DT	B-NP
O	3754	3757	EBV	EBV	NN	I-NP
O	3758	3768	antibodies	antibody	NNS	I-NP
O	3769	3772	and	and	CC	I-NP
O	3773	3781	confirms	confirm	NNS	I-NP
O	3782	3786	that	that	IN	B-SBAR
O	3787	3796	different	different	JJ	B-NP
O	3797	3805	peptides	peptide	NNS	I-NP
O	3806	3809	are	be	VBP	B-VP
O	3810	3818	required	require	VBN	I-VP
O	3819	3821	to	to	TO	I-VP
O	3822	3831	represent	represent	VB	I-VP
O	3832	3841	different	different	JJ	B-NP
O	3842	3850	epitopes	epitope	NNS	I-NP
O	3850	3851	.	.	.	O

O	3852	3861	Therefore	Therefore	RB	B-ADVP
O	3861	3862	,	,	,	O
O	3863	3864	a	a	DT	B-NP
O	3865	3876	combination	combination	NN	I-NP
O	3877	3879	of	of	IN	B-PP
O	3880	3883	Eb1	Eb1	NN	B-NP
O	3884	3891	peptide	peptide	NN	I-NP
O	3892	3894	F1	F1	NN	I-NP
O	3895	3898	and	and	CC	O
O	3899	3904	Gp125	Gp125	NN	B-NP
O	3905	3913	peptides	peptide	NNS	I-NP
O	3914	3919	could	could	MD	B-VP
O	3920	3922	be	be	VB	I-VP
O	3923	3933	recognised	recognise	VBN	I-VP
O	3934	3936	by	by	IN	B-PP
O	3937	3947	antibodies	antibody	NNS	B-NP
O	3948	3955	present	present	JJ	B-ADJP
O	3956	3958	in	in	IN	B-PP
O	3959	3962	all	all	PDT	B-NP
O	3963	3967	this	this	DT	I-NP
O	3968	3971	set	set	NN	I-NP
O	3972	3974	of	of	IN	B-PP
O	3975	3978	EBV	EBV	NN	B-NP
O	3979	3987	clinical	clinical	JJ	B-NP
B-Organism_substance	3988	3995	samples	sample	NNS	I-NP
O	3996	4005	resulting	result	VBG	B-VP
O	4006	4008	in	in	IN	B-PP
O	4009	4012	100	100	CD	B-NP
O	4012	4013	%	%	NN	I-NP
O	4014	4025	sensitivity	sensitivity	NN	I-NP
O	4025	4026	.	.	.	O

O	4027	4030	For	For	IN	B-PP
O	4031	4034	the	the	DT	B-NP
B-Organism_substance	4035	4042	samples	sample	NNS	I-NP
O	4043	4050	defined	define	VBN	B-VP
O	4051	4053	as	as	IN	B-PP
O	4054	4057	EBV	EBV	NN	B-NP
O	4057	4058	-	-	HYPH	B-VP
O	4058	4070	seronegative	seronegative	JJ	B-ADJP
O	4070	4071	,	,	,	O
O	4072	4077	there	there	EX	B-NP
O	4078	4082	were	be	VBD	B-VP
O	4083	4085	no	no	DT	B-NP
O	4086	4094	readings	reading	NNS	I-NP
O	4095	4100	above	above	IN	B-PP
O	4101	4104	the	the	DT	B-NP
O	4105	4108	cut	cut	VB	I-NP
O	4108	4109	-	-	HYPH	B-VP
O	4109	4112	off	off	RP	B-PRT
O	4113	4118	level	level	NN	B-NP
O	4119	4122	and	and	CC	O
O	4123	4132	therefore	therefore	RB	B-ADVP
O	4133	4135	no	no	DT	B-NP
O	4136	4141	false	false	JJ	I-NP
O	4142	4151	positives	positive	NNS	I-NP
O	4151	4152	,	,	,	O
O	4153	4162	resulting	result	VBG	B-VP
O	4163	4165	in	in	IN	B-PP
O	4166	4169	100	100	CD	B-NP
O	4169	4170	%	%	NN	I-NP
O	4171	4182	specificity	specificity	NN	I-NP
O	4182	4183	.	.	.	O

O	4184	4186	In	In	IN	B-PP
O	4187	4195	addition	addition	NN	B-NP
O	4195	4196	,	,	,	O
O	4197	4202	there	there	EX	B-NP
O	4203	4207	were	be	VBD	B-VP
O	4208	4210	no	no	DT	B-NP
O	4211	4221	absorbance	absorbance	NN	I-NP
O	4222	4230	readings	reading	NNS	I-NP
O	4231	4236	above	above	IN	B-PP
O	4237	4240	the	the	DT	B-NP
O	4241	4244	cut	cut	VB	I-NP
O	4244	4245	-	-	HYPH	B-ADJP
O	4245	4248	off	off	RP	B-PRT
O	4249	4255	levels	level	NNS	B-NP
O	4256	4259	for	for	IN	B-PP
O	4260	4263	the	the	DT	B-NP
O	4264	4275	potentially	potentially	RB	I-NP
O	4276	4281	cross	cross	AFX	I-NP
O	4281	4282	-	-	HYPH	I-NP
O	4282	4290	reactive	reactive	JJ	I-NP
B-Organism_substance	4291	4296	serum	serum	NN	I-NP
I-Organism_substance	4297	4304	samples	sample	NNS	I-NP
O	4304	4305	,	,	,	O
O	4306	4315	inferring	infer	VBG	B-VP
O	4316	4320	that	that	IN	B-SBAR
O	4321	4324	the	the	DT	B-NP
O	4325	4333	peptides	peptide	NNS	I-NP
O	4334	4344	identified	identify	VBN	B-VP
O	4345	4347	in	in	IN	B-PP
O	4348	4352	this	this	DT	B-NP
O	4353	4358	study	study	NN	I-NP
O	4359	4363	have	have	VBP	B-VP
O	4364	4368	high	high	JJ	B-NP
O	4369	4380	specificity	specificity	NN	I-NP
O	4381	4384	for	for	IN	B-PP
O	4385	4388	EBV	EBV	NN	B-NP
O	4389	4399	antibodies	antibody	NNS	I-NP
O	4399	4400	.	.	.	O

